Immunotherapy following chemotherapy offers extended survival to patients with advanced urothelial cancer

'Study shows the largest survival benefit seen to date in advanced urothelial cancer,' said ASCO President Howard Burris

Like Comment

Treatment with avelumab combined with best supportive care following chemotherapy significantly extended overall survival compared with best supportive care alone in patients with advanced urothelial cancer in the JAVELIN Bladder 100 trial.

The results of this study were presented as part of the virtual scientific programme of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. 

Study at a Glance 

Focus 

Avelumab as maintenance therapy in patients with unresectable locally advanced or metastatic urothelial cancer 

Population 

700 patients with disease that had responded to chemotherapy 

Findings 

Avelumab improved overall survival by 7.1 months over best supportive care 

Significance 

Supports the use of avelumab as a maintenance treatment following initial chemotherapy 

To view full article and watch the video summary,
register to OnMedica and then click
'View full content'.

 

OnMedica

Editorial team, Wilmington Healthcare

OnMedica is an independent, easy to access on-the-go website for doctors. It provides GPs and specialists with easy to digest and up-to-date, relevant educational content whilst enabling the freedom to share and collaborate in a safe-space to further personal development.
2983 Contributions
43 Followers
1 Following

No comments yet.